Analysis of Expression of Programmed Cell Death 1 Ligand 1 (Pd-L1) in Malignant Pleural Mesothelioma (Mpm)

  • Cedres S
  • Ponce Aix S
  • Zugazagoitia J
  • et al.
N/ACitations
Citations of this article
1Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: The increasing incidence and poor outcome associated with MPM requires to find effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is expressed in many different human cancers but its role in MPM has yet to be established. The aim of this study is to evaluate the expression of PD-L1 in MPM Methods: 119 MPM patients (p) from Vall d'Hebron University Hospital and 12 Octubre University Hospital between November 2002 and February 2014 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained with anti-PD-L1 (clone E1L3N) and intensity was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). Cases showing more than 1% expression of PD-L1 were considered positive. Survival data were calculated by the Kaplan-Meier method. The associations of PD-L1 expression with outcome were assessed with Cox regression models. Results: Patient's characteristics: median age 69 years (42-90 years), males: 71.4%, PS 1:64.9%, asbestos exposure: 45%, stage III: 39%, epithelial subtype: 65.5%. PD-L1 was analyzed in 77 p and was positive in 20.7% p (14 samples in membrane, 16 in cytoplasm and 2 in immune infiltrate). PD-L1 intensity was weak in 56.2%, moderate in 25% and strong in 18.7% p. There was no significant relationship between PD-L1 expression and gender, smoking status, asbestos exposure, stage, and lymphocytic infiltration between PD-L1 positive and negative. We found differences in expression PD-L1 according to histology: PD-L1 expression was more frequent in no-epithelial tumor, 60% v 15% in epithelial; p = 0.033. The median survival in all population was 13.8 months, and for PD-L1 analysis patients, median survival in p PD-L1 positive was 4.79 vs 16.3 months in p PD-L1 negative (p = 0.012). Conclusions: We have shown PD-L1 is expressed in 20% of p and is a prognostic marker in MPM. Our results suggest PD-L1 warrants further exploration in selecting p for immunotherapy Disclosure: All authors have declared no conflicts of interest.

Cite

CITATION STYLE

APA

Cedres, S., Ponce Aix, S., Zugazagoitia, J., Anguita, A. B., Sansano, I., Navarro Mendivil, A., … Felip, E. (2014). Analysis of Expression of Programmed Cell Death 1 Ligand 1 (Pd-L1) in Malignant Pleural Mesothelioma (Mpm). Annals of Oncology, 25, v1. https://doi.org/10.1093/annonc/mdu438.66

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free